NFKB1 and breast carcinoma: Although a previous phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer found a moderate antitumor effect in heavily pretreated patients43, breast cancer patients with an activated NF-κB pathway might benefit from bortezomib treatment.